Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Excelsior BiopharmaROCO:6496 51 Days Inventory is 165.23 as of Dec. 2025, which is 43% above its 10-year median of 115.51. GuruFocus rates ROCO:6496 with a GF Score™ of 51/100 and a GF Value™ of NT$36.03 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Excelsior Biopharma ranks worse than 64.79% on this metric.
The historical rank and industry rank for Excelsior Biopharma's Days Inventory or its related term are showing as below:
ROCO:6496'
s Days Inventory Range Over the Past 10 Years
Min: 82.04 Med: 115.51 Max: 202.36
Current: 202.36
During the past 13 years, Excelsior Biopharma's highest Days Inventory was 202.36. The lowest was 82.04. And the median was 115.51.
ROCO:6496's Days Inventory is ranked worse than 64.79% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs ROCO:6496: 202.36
Excelsior Biopharma's Days Inventory
declined
from Dec. 2024 (179.14) to Dec. 2025 (165.23).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Excelsior Biopharma's Inventory Turnover for the
three
months ended in Dec. 2025 was 0.55.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Excelsior Biopharma's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 1.08.
Excelsior Biopharma (ROCO:6496) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Excelsior Biopharma's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Excelsior Biopharma's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Excelsior Biopharma Days Inventory Related Terms
Excelsior Biopharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Excelsior Biopharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Biopharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Excelsior Biopharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Excelsior Biopharma (ROCO:6496) has a Days Inventory of 165.23 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Excelsior Biopharma and its competitors. This is 43% above median its historical median of 115.51. Over the past decade, Excelsior Biopharma's Days Inventory has ranged from 82.04 to 202.36. According to the industry distribution chart, Excelsior Biopharma ranks #598 out of 923 companies in the Drug Manufacturers industry, placing it in the top 64.8%.
Is Excelsior Biopharma's Days Inventory too high?
Excelsior Biopharma's current Days Inventory of 165.23 is 43% above median its 10-year median of 115.51. Over the past 10 years, this metric has ranged from a low of 82.04 to a high of 202.36. The Drug Manufacturers industry median Days Inventory is 164.38. Excelsior Biopharma's value of 165.23 is 0.5% above this industry median. Based on the distribution chart, Excelsior Biopharma ranks #598 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Excelsior Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Excelsior Biopharma ranks #598 out of 923 companies for Days Inventory. This places Excelsior Biopharma in the lower half of its industry. The industry median Days Inventory is 164.38. Excelsior Biopharma's value of 165.23 is 0.5% above this benchmark. Historically, Excelsior Biopharma's own Days Inventory has ranged from 82.04 to 202.36 over the past decade. While the company's 10-year median is 115.51 vs. the industry median of 164.38, Excelsior Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Excelsior Biopharma's current Days Inventory of 165.23 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Excelsior Biopharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Excelsior Biopharma's current Days Inventory is 165.23, which is 43% above median its own 10-year median of 115.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.03, compared to a current price of NT$25.00 — trading 30.6% below its estimated fair value. The current Days Inventory is 165.23, which is 43% above median its 10-year median of 115.51 and 0.5% above the Drug Manufacturers industry median of 164.38. Excelsior Biopharma's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current Days Inventory is 165.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued.
The current stock price of NT$25.00 is trading 30.6% below its estimated GF Value™ of NT$36.03.
GuruFocus considers Excelsior Biopharma to be Possible Value Trap.
Key valuation signals for ROCO:6496:
Days Inventory: 165.23 (43% above median its 10-year median of 115.51)
GF Value™: NT$36.03 vs. price of NT$25.00 (30.6% below fair value)
Industry Position: 0.5% above the Drug Manufacturers median (#598 of 923)
No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
51GF Score
Get the complete analysis for ROCO:6496
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6496 has been successfully added to your 
